Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14135342 | 1.00 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAADRD2 | |
| SCHEMBL15217044 | 1.00 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAADRD2 | |
| SCHEMBL24965969 | 1.00 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAADRD2 | |
| SCHEMBL3090051 | 0.88 | SIGMAR1 (0.58) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL4599655 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL4599654 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL3100817 | 0.86 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL6488211 | 0.85 | SIGMAR1 (0.55) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL3106101 | 0.85 | SIGMAR1 (0.55) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL6376833 | 0.83 | SIGMAR1 (0.47) | SIGMAR1CHRM2CHRM1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-8980965-B2 | Method for producing polyester type flexible polyurethane foam, and catalyst composition to be used therefor | TOSOH CORPORATION (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | TOSOH CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204394-A1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | Tosoh Corporation (JP) | 2010-07-07 | — | — | EP | disclosed |
| EP-0861660-B9 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORP (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-0861660-B1 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORP (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-0787494-B1 | Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori | KANEKA CORP (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-5981522-A | ADMINISTERING RIFAMYCIN DERIVATIVE TO THE PATIENT TO TREAT GASTRITIS, GASTRODUODENITIS, EROSIVE GASTRITIS, GASTRIC EROSION, EROSIVE DUODENITIS, GASTRIC ULCER AND DUODENAL ULCER CAUSED BY HELICOBACTER PLORI | KANEKA CORPORATION (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0861660-A1 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORPORATION (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0787494-A1 | REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER | KANEKA CORPORATION (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | OR51E2, CYP4F11, FFAR3 | SIGMAR1 299/4885CHRM2 175/4885CHRM1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.